By Shawn M. Carter
While SGLT2 inhibitors are often associated with bone and mineral metabolism irregularities, it remains unclear if these are linked to higher fracture risk in patients with chronic kidney disease, according to recently published research. Read the full article in Healio.
In this episode of Hot Topics in Kidney Health, Dr. Katherine Tuttle, Executive Director for Research at Providence Health Care, and Jane DeMeis, kidney patient and advocate, discuss a promising new drug that was initially developed to help patients maintain blood sugar levels and are now being used as in the prevention and treatment of kidney disease.
Read the complete article and/or listen to the recording on this topic from National Kidney Foundation here.